webleads-tracker

Home  >  MEDTECH  > Caliper's Microfluidic Technologies enable 510(k) approved ...
  >  MEDTECH BUSINESS/MARKET
Mar 7th, 2011
 
Caliper's Microfluidic Technologies enable 510(k) approved multiplexed immunoassay system for liver cancer risk assessment
 
Wako diagnostics obtains 510(k) FDA clearance to market its uTASWako® i30 immunoanalyzer system in the U.S. to clinical laboratories
Send to a friend

Caliper Life Sciences, Inc. (Nasdaq: CALP) announced that its licensee Wako Pure Chemical Industries, through its Wako Diagnostics division, has obtained 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its uTASWako® i30 Immunoanalyzer and AFP-L3 and DCP Assays, which are used to assess liver cancer risk in patients with chronic liver disease.  The i30 Immunoanalyzer, which incorporates Caliper's microfluidic LabChip® technologies, utilizes microfluidics to integrate sampling, mixing, separation and detection of up to six analytes.  The system is currently marketed in Japan by Wako as an in vitro diagnostic (IVD) platform.

"Wako was an early adopter of Caliper's microfluidic LabChip technology and the 510(k) approval for the uTASWako i30 Immunoanalyzer instrument and associated diagnostic tests is an important milestone in the validation of microfluidics as a valuable platform for diagnostics," said Kevin Hrusovsky, President and CEO of Caliper Life Sciences.  "Caliper's microfluidic technologies are playing an increasing role in diagnostics through our licensees such as Wako, Becton Dickinson, Canon, as well as through Caliper's own direct channel.  Partnerships, like the recently announced Sony DADC collaboration, have uniquely positioned Caliper to develop breakthrough diagnostic solutions based on high volume plastic consumable manufacturing capabilities."

Caliper recently announced the LabChip Dx multiplexed reader, which utilizes innovative microfluidics technology to perform reproducible, high-resolution, electrophoretic separations for analyzing multiplex PCR products.  Developed in collaboration with Seegene, the LabChip Dx is based on the same approach that has become the standard, microfluidic based, electrophoretic separation platform in life sciences research, enabling high throughput, multiplex, cost effective sample processing for discovery and validation of molecular and companion diagnostics.  The cost-effective approach of Caliper's robust microfluidics technology explains its high rate of adoption among research laboratories around the world. 

About Caliper Life Sciences
Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to develop life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results that translate into potential cures for a range of diseases. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, molecular imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com.

Caliper and LabChip are registered trademarks of Caliper Life Sciences, Inc.  uTASWako is a registered trademark of Wako Pure Chemical Industries.  Sony and DADC are registered trademarks of Sony Corporation. 

 

null

 

null

 

null

 

null

 

null


 
More MEDTECH BUSINESS/MARKET news

Jul 20th
May 17th
Apr 8th
Mar 3rd
Mar 3rd
 
©2007 Yole Developpement All rights reserved                  Disclaimer | Legal notice | To advertise
Yole Développement: Le Quartz, 75 cours Emile Zola, 69100 Villeurbanne, France. TEL: (33) 472 83 01 80 FAX: (33) 472 83 01 83 E-Mail: info @yole.fr